Abstract:Introduction Allopurinol is a hypouricemic drug that has been prescribed since 1963. It is one of the most common drugs that induce Severe Cutaneous Adverse Reactions (SCARs), namely Stevens Johnson syndrome (SJS)/Lyell syndrome (LS) and DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms). In our hospital series, we report cases of SCARs attributed to allopurinol in order to sensitize prescribers to the risk of its misuse. Patients and methods We carried out a retrospective study from 2011 to 2021 of patients hospitalized at our dermatology department for SCARs induced by allopurinol. Imputability was confirmed by the French methodology of Bégaud et al. Results We identified 31 cases. The median age was 63 years (26–83). The sex-ratio (M/F) was 0.34. Twenty-two point five percent of patients were being followed for chronic renal disease. Allopurinol was prescribed in 77.4% cases for laboratory indications of asymptomatic hyperuricemia. Combined use with a thiazide diuretic was found in 51.6% of patients. The clinical forms were: 21 DRESS syndrome, 5 LS, 2 overlap syndrome and 3 SJS. The median time to onset of clinical signs was 4 days to 5 weeks for SJS/LS and 2 to 8 weeks for DRESS. Complications were as follows: renal failure (48.3%), hepatic cytolysis (51.6%), electrolyte imbalance in (54.8%), severe sepsis (16.6%) and corneal ulcer (6.4%). Major hypereosinophilia was noted in 48.3% of cases and was significantly associated with hepatic cytolysis ( P = 0.014). Five patients required a stay in the intensive care unit, with death occurring in 12.9%. Conclusion Despite its capacity to cause life-threatening SCARs, allopurinol continues to be prescribed in most cases of asymptomatic hyperuricemia. Such misuse in terms of indication and follow-up warrants the raising of physicians' awareness concerning the benefit/risk ratio. Résumé Introduction L'allopurinol est un hypo-uricémiant pourvoyeur de toxidermies graves parfois mortelles à savoir le syndrome de Stevens Johnson (SSJ)/Lyell (SL) et le DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome. Nous rapportons à travers notre série hospitalière les effets indésirables graves cutanés et viscéraux imputés à l'allopurinol afin de sensibiliser les prescripteurs au risque de son mésusage. Patients et méthodes Étude rétrospective allant de 2011 à 2021 des patients hospitalisés pour toxidermie grave causée par l'allopurinol dans notre département de dermatologie. L'imputabilité à l'allopurinol était confirmée par la méthodologie française de Bégaud et al. Résultats Nous avons recensé 31 cas. L'âge médian est de 63 ans (26–83). Le sex-ratio (H/F) : 0,34. Sept patients (22,5 %) étaient suivis pour maladie rénale chronique. L'allopurinol était prescrit chez 77,4 % devant une hyper uricémie biologique et asymptomatique. L'association à un diurétique thiazidique était retrouvée chez 51,6 %. Les formes cliniques étaient: 21 syndromes de DRESS, 5 SL, 2 SC et 3 SSJ. Le délai médian de survenue des signes cliniques était de 4 jours à 5 semaines pour le SSJ/SL et de 2 à 8 semaines pour le DRESS. Les complications étaient: insuffisance rénale fonctionnelle chez 48,3 %, cytolyse hépatique chez 51,6 %, des troubles hydro-électrolytiques chez 54,8 %, un sepsis grave chez 16,6 % et un ulcère de cornée chez 6,4%. Une hyper éosinophilie majeure a été retrouvée chez 48,3 % qui est significativement associée à une atteinte hépatique (valeur p = 0,014). Cinq patients ont nécessité un séjour en réanimation avec décès chez 12,9 %. Conclusion L'allopurinol est pourvoyeur de toxidermies graves pouvant engager le pronostic vital. Il est prescrit dans la plupart des cas devant une hyper uricémie asymptomatique. Cette mauvaise utilisation en termes d'indication et de suivi justifie une sensibilisation des médecins à bien mesurer le bénéfice/risque.

Prevention of allopurinol-associated adverse cutaneous drug reactions in high-risk patient groups in Canada

Heart disease and the risk of allopurinol-associated severe cutaneous adverse reactions: a general population–based cohort study

A Case of Drug Hypersensitivity Syndrome Caused by Allopurinol

Allopurinol: Clinical Considerations in the Development and Treatment of Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and Other Associated Drug Reactions

Initiation Dose of Allopurinol and the Risk of Severe Cutaneous Reactions in Older Adults With CKD: A Population-Based Cohort Study

Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin

Allopurinol hypersensitivity syndrome

Allopurinol induced severe cutaneous adverse reactions: Vigilance of prescription (31 cases)

Allopurinol-Induced Severe Cutaneous Adverse Drug Reactions: An Analysis of Spontaneous Reports in Malaysia (2000–2018)

Delayed hypersensitivity reaction to allopurinol: A case report

ALLOPURINOL INDUCED ADVERSE DRUG REACTIONS: CASE SERIES

Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study

HLA-B*58:01 screening to prevent allopurinol-induced severe cutaneous adverse reactions in Chinese patients with chronic kidney disease

Allopurinol: Intravenous Use for Prevention and Treatment of Hyperuricemia

Analysis of adverse reactions caused by allopurinol in Beijing

Allopurinol-induced hypersensitivity syndrome in an anti-neutrophil cytoplasmic antibody-associated systemic vasculitis patient with renal injury

HLA-B*5801 testing: Is it time to consider mandatory testing prior to prescribing allopurinol in Singapore?

Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies

Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles

Risk of cutaneous adverse reactions associated with allopurinol or febuxostat in real‐world patients: A nationwide study

Study on the relationship between HLA-B * 5801 and severe cutaneous adverse reactions caused by allopurinol